

## Implementation of a Third-Party Allocation of New Shares

**Tokyo, Japan (August 31, 2022)** - Noile-Immune Biotech Inc. (“Noile-Immune”) today announced offering of new shares through a third-party allocation to MEDIPAL Innovation Investment LPS, a corporate venture capital (CVC) fund established by MEDIPAL HOLDINGS CORPORATION.

With this funding, Noile-Immune focuses efforts to deliver safe and effective treatment options to patients suffering from cancer worldwide as soon as possible, through steady progress of in-house clinical studies and R&D projects, and further expansion of co-pipelines with licensing partnership, and aims to the arrival of an era when we can overcome cancer.

### About MEDIPAL Innovation Investment LPS

MEDIPAL is mainly engaged in the wholesale business in the pharmaceutical, health and beauty fields. In the Prescription Pharmaceutical Wholesale Business, one of its core business segments, MEDIPAL contributes to the development of pharmaceuticals, medical equipment, regenerative medicine and other products through unique initiatives that support startup companies from early-stage development to post-launch distribution.

As part of these initiatives, MEDIPAL jointly established MEDIPAL Innovation Investment LPS in March 2021 with SBI Investment Co., Ltd. (“SBI Investment”), a wholly owned subsidiary of SBI Holdings Inc. since its establishment.

**Noile-Immune Biotech, Inc., established as a university start-up, aims to contribute to the arrival of an era when we can overcome cancer through the next-generation cancer immunotherapies, centering on PRIME technology.**

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech, Inc.

Department of Administration

E-mail: [ir@noile-immune.com](mailto:ir@noile-immune.com)